Literature DB >> 9403321

Insulin regulation of human ovarian androgens.

J E Nestler1.   

Abstract

Hyperinsulinaemic insulin resistance is characteristic of many, if not all, women with polycystic ovary syndrome (PCOS). We will review evidence suggesting that hyperinsulinaemia promotes hyperandrogenism in PCOS by two distinct and independent mechanisms: (i) by increasing circulating ovarian androgens; and (ii) by directly reducing serum sex hormone-binding globulin concentrations. The net result of these actions is to increase circulating free testosterone concentrations. It appears likely that an inherent (probably genetically determined) ovarian defect need be present in women with PCOS, which makes the ovary susceptible to insulin stimulation of androgen production. Limited evidence suggests that hyperinsulinaemia might also promote ovarian androgen production by influencing pituitary release of gonadotrophins. This latter possibility, however, has not been critically evaluated. The clinical implication of these findings is that amelioration of hyperandrogenism in women with PCOS may be achieved by interventions which improve insulin sensitivity and reduce circulating insulin. Such measures might include, but are not limited to, weight loss, dietary modification, and insulin-sensitizing medications.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9403321     DOI: 10.1093/humrep/12.suppl_1.53

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  25 in total

1.  Differential effects of insulin sensitivity on androgens in obese women with polycystic ovary syndrome or normal ovulation.

Authors:  Tomoko Asagami; Tyson H Holmes; Gerald Reaven
Journal:  Metabolism       Date:  2008-10       Impact factor: 8.694

Review 2.  Polycystic ovarian syndrome: the metabolic syndrome comes to gynaecology.

Authors:  Z E Hopkinson; N Sattar; R Fleming; I A Greer
Journal:  BMJ       Date:  1998-08-01

Review 3.  How actual is the dietary treatment in overweighting patients with polycystic ovary syndrome?

Authors:  C Cortet-Rudelli; D Dewailly
Journal:  J Endocrinol Invest       Date:  1998-10       Impact factor: 4.256

4.  Intrauterine Growth Restriction and Hypertrophic Cardiomyopathy as Prenatal Ultrasound Findings in a Case of Leprechaunism.

Authors:  Kevin Perge; Mona Massoud; Hélène Gauthier-Moulinier; Olivier Lascols; Nicolas Pangaud; Carine Villanueva; Linda Pons
Journal:  Mol Syndromol       Date:  2020-09-02

Review 5.  Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome.

Authors:  Daniel A Dumesic; Sharon E Oberfield; Elisabet Stener-Victorin; John C Marshall; Joop S Laven; Richard S Legro
Journal:  Endocr Rev       Date:  2015-10       Impact factor: 19.871

6.  Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial.

Authors:  Etelka Moll; Patrick M M Bossuyt; Johanna C Korevaar; Cornelis B Lambalk; Fulco van der Veen
Journal:  BMJ       Date:  2006-06-12

7.  Binge eating and menstrual dysfunction.

Authors:  Monica Algars; Lu Huang; Ann F Von Holle; Christine M Peat; Laura M Thornton; Paul Lichtenstein; Cynthia M Bulik
Journal:  J Psychosom Res       Date:  2013-11-28       Impact factor: 3.006

8.  Comparison of hormonal and metabolic markers after a high-fat, Western meal versus a low-fat, high-fiber meal in women with polycystic ovary syndrome.

Authors:  Heather I Katcher; Allen R Kunselman; Romana Dmitrovic; Laurence M Demers; Carol L Gnatuk; Penny M Kris-Etherton; Richard S Legro
Journal:  Fertil Steril       Date:  2008-03-10       Impact factor: 7.329

9.  An internet-based prospective study of body size and time-to-pregnancy.

Authors:  Lauren A Wise; Kenneth J Rothman; Ellen M Mikkelsen; Henrik Toft Sørensen; Anders Riis; Elizabeth E Hatch
Journal:  Hum Reprod       Date:  2009-10-14       Impact factor: 6.918

Review 10.  Finasteride in Hidradenitis Suppurativa: A "Male" Therapy for a Predominantly "Female" Disease.

Authors:  Birgit N Khandalavala; Melissa Voutsalath Do
Journal:  J Clin Aesthet Dermatol       Date:  2016-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.